NuPathe Inc.

NuPathe — Investor Presentation (September 2013)

32 slides from NuPathe's investor presentation, Sep 11, 2013

  1. Slide 1: Corporate Presentation

    Corporate Presentation September 11, 2013 © 2013 NuPathe Inc. All rights reserved.

  2. Slide 2: Forward-Looking Statements

    2 Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All remarks and information that are not historical facts are hereby identified as forward-looking statements for this purpose and include,

  3. Slide 3: NuPathe: A Specialty CNS Pharmaceutical Company

    3 • ZECUITY® – the first and only FDA-approved migraine patch •31 million migraine sufferers in the U.S. •Significant unmet need – migraine-related nausea (MRN) •Focused on key objectives •Preparing for 4Q13 launch •Securing commercial partners for ZECUITY •Two early-stage CNS drug candidates •Schiz

  4. Slide 4: ZECUITY - First and Only FDA Approved Migraine Patch

    4 •Game-changing disruptive technology for migraine .Delivers sumatriptan, the #1 prescribed migraine medication .Five Orange-Book listed patents provide protection to April 2029 •Uniquely positioned to address migraine headache pain and MRN .Rapid relief of both headache pain and MRN with a low rat

  5. Slide 5: ZECUITY: Game-Changing, Disruptive Technology

    5 •Intelligent, active transdermal delivery .Microprocessor supports highly controlled and consistent delivery •Multiple safety checks within seconds of activation •Continuous monitors skin resistance and adjusts drug delivery •Delivers 6.5 mg of sumatriptan with minimal patient-to-patient variabili

  6. Slide 6: ZECUITY: First and Only Migraine Patch

    6 Easy to use, single-use, disposable •Applied to upper arm or thigh during a migraine •Bypasses GI tract •Rapidly delivers sumatriptan ZECUITY: First and Only Migraine Patch

  7. Slide 7: MRN is a Prominent Component of Migraine Disease Burden

    7 MRN is a Prominent Component of Migraine Disease Burden 31M 16M 8M 0 5 10 15 20 25 30 35 Adult Migraine Sufferers Diagnosed & Treated MRN in Majority of Attacks U.S. Adults (millions) Core Zecuity Target Patients •Affects females to males 3:13 •Disease of the working class population, 20 – 50 year

  8. Slide 8: Large Market Opportunity with Significant Unmet Disease Burden

    8 Large Market Opportunity with Significant Unmet Disease Burden •~8 million patients experience MRN in a majority of their attacks1,2,3 •Patients with MRN at time of treatment are less likely to respond to oral triptans4,5 •Migraineurs with frequent MRN drive higher direct medical costs than patien

  9. Slide 9: Current Options Often Fail Patients with MRN

    9 •Triptan tablets/melts .Patients delay/avoid orals – too nauseated/fear of vomiting1,2,3 .Gastroparesis can impact absorption and response to oral triptans4 •Triptan nasal sprays and injections •Result: Patients frequently switch7 .80% have tried at least two triptans .50% have tried three or more

  10. Slide 10: ZECUITY is the Solution

    10 ZECUITY is tailored for migraine patients who suffer from MRN ZECUITY is the Solution

  11. Slide 11: Excellent Efficacy and Safety Demonstrated through Robust Clinical Program

    11 •Extensive clinical program including more than 800 patients and 10,000 patch applications •Pivotal Phase 3 study (n=530) published in Headache, Oct 2012 •Two 12-month, repeat use, open-label trials (n=662) .NP101-008 published in Headache, April 2012 Excellent Efficacy and Safety Demonstrated th

  12. Slide 12: Pivotal Phase 3 Data Published in HEADACHE Oct 2012

    12 •Pain relief and nausea freedom two-hours following patch activation .Twice as many patients treated with ZECUITY achieve freedom from headache pain compared to placebo .53% of patients treated with ZECUITY achieved relief from headache pain compared with 29% for placebo .84% of patients treated

  13. Slide 13: Clinical Data – Zecuity and Imitrex Tablets

    13 Clinical Data – Zecuity and Imitrex® Tablets 57% 68% 65% 20% 40% 60% 80% 100% Placebo Tab Imitrex® 50mg Imitrex® 100mg * * * * ns ns Imitrex® % Patients w/ Headache Pain Relief ZECUITY % Patients w/ Headache Pain Relief Zecuity % Patients w/ Nausea Freedom Imitrex® % Patients w/ Nausea Freedom 29

  14. Slide 14: ZECUITY Associated with Substantially Less Treatment Emergent Nausea

    14 •TEN is defined as the development of MRN after initiation of treatment •Up to 20% of patients receiving oral triptans experience TEN1 •In ZECUITY pivotal Phase 3, at two hours post- treatment2: .5% of ZECUITY patients had TEN* .14% of placebo patients had TEN* ZECUITY Associated with Substantial

  15. Slide 15: Pivotal Phase Data Adverse Event Profile

    15 Pivotal Phase 3 Data Adverse Event Profile •Application site events were typical of patches .Majority were mild in intensity and transient •Most patients experience some skin redness (typically goes away in 24hrs) •Low incidence of adverse events known as triptan sensations •Compared with product

  16. Slide 16: Two 12-Month Open-Label Trials Confirm Safety of ZECUITY

    16 Two 12-Month Open-Label Trials Confirm Safety of ZECUITY (n=662 patients) •Consistent relief of pain and nausea over 12 months •Very low incidence of triptan sensations (0.9%) •No increased skin irritation with repeat or increased use •Low incidence of allergic contact dermatitis (4%) •12-month c

  17. Slide 17: ZECUITY Delivers Consistent Relief of Pain and Nausea Over 12 Months

    17 0% 20% 40% 60% 80% 100% 1 2 3 4 5 6 7 8 9 10 11 12 % of Patients Treatment Month Headache Pain Relief at 2 Hours Nausea Free at 2 Hours ZECUITY Delivers Consistent Relief of Pain and Nausea Over 12 Months

  18. Slide 18: ZECUITY Marketing Strategy

    18 •Target physicians who treat higher % of MRN .~6,000 headache specialists prescribe 33+ million triptan units annually .Additional ~34,000 physicians prescribe 50+ million triptan units annually •Relentlessly deliver differentiating messages in label .Relief of both headache pain and MRN .Low rat

  19. Slide 19: Powerful Marketing Messages Supported by the ZECUITY Label

    19 Powerful Marketing Messages Supported by the ZECUITY Label Relief of BOTH Headache Pain and Nausea Low Incidence of Triptan Sensations Key Message for ZECUITY Approved ZECUITY Label Freedom from Headache Pain (1st and ONLY triptan to have headache pain free as a primary endpoint) SECTION 14: CLIN

  20. Slide 20: Extensive ZECUITY Market Research Conducted in Preparation for Launch

    20 Extensive ZECUITY Market Research Conducted in Preparation for Launch Physicians (n=770) •Message Testing •MD Segmentation •Product Positioning •Quantitative MD Concept Testing •Qualitative Concept Testing Patients (n=839) •Attribute Testing •Patient Segmentation •Commercial Packaging & Patient I

  21. Slide 21: Pricing and Reimbursement Aligned with Product Positioning

    21 •Insurance is >90% commercial private pay •Payors see value in ZECUITY for migraine .Recognize cost of poorly controlled migraine patients .Acknowledge GI issues as a problem •Broad formulary access expected .Tier 3 with a single step edit – parity to other brands •Aligned with product positionin

  22. Slide 22: Quantitative Research Confirms the Market Opportunity for ZECUITY

    22 •Physicians rated ZECUITY superior to oral, nasal, and injectable triptans for MRN patients on key attributes including: .Ability to use early in a migraine attack despite GI issues .Frequency of triptan sensations and overall tolerability .Elimination of nausea at 1 and at 2 hours •77% of MRN pa

  23. Slide 23: Physicians Indicate Strong Preference for ZECUITY Over Orals for MRN Patients

    23 Physicians Indicate Strong Preference for ZECUITY Over Orals for MRN Patients Ability to use early in attack despite GI issues Frequency of triptan related AEs Overall tolerability Nausea free at 2 hours Nausea free at 1 hour Effective in one dose Pain relief at 2 hours Speed of onset Pain relief

  24. Slide 24: Physicians Indicate ZECUITY Preferable to Nasal Triptans

    24 Physicians Indicate ZECUITY Preferable to Nasal Triptans Ability to use early in attack despite GI issues Frequency of triptan related AEs Overall tolerability Nausea free at 2 hours Nausea free at 1 hour Effective in one dose Pain relief at 2 hours Speed of onset Pain relief at 1 hour Ease of us

  25. Slide 25: Physicians Rate ZECUITY Superior to Injectable Triptans

    25 Physicians Rate ZECUITY Tolerability and Ease of Use Superior to Injectable Triptans Ability to use early in attack despite GI issues Frequency of triptan related AEs Overall tolerability Nausea free at 2 hours Nausea free at 1 hour Effective in one dose Pain relief at 2 hours Speed of onset Pain

  26. Slide 26: Current Oral Triptan Users Expected to Be Significant Source of Patients

    26 82% 9% 9% Expected Source of Zecuity Patients From Existing Triptan Users Oral Nasal Injection Current Oral Triptan Users Expected to Be Significant Source of ZECUITY Patients Patient’s Current Triptan Formulation Oral Nasal Injection Triptan Market: Share of Patients1 85.9% 6.7% 7.4% Top Box- “V

  27. Slide 27: ZECUITY Brand Positioning is Distinct, Meaningful, Sustainable

    27 ZECUITY Brand Positioning is Distinct, Meaningful, Sustainable ZECUITY will become the acute migraine treatment of choice for patients who suffer from migraine related nausea. . Game-changing, disruptive technology that bypasses GI tract . Addresses both headache pain and migraine-related nausea

  28. Slide 28: Illustrative Market Segment Opportunity

    28 •~8 million patients experience MRN in a majority of attacks •Treat 24 migraines per year •ZECUITY WAC pricing of $100 or $150/patch Illustrative Market Segment Opportunity $96 $192 $288 $384 $480 $144 $288 $432 $576 $720 $0 $100 $200 $300 $400 $500 $600 $700 $800 0.5% 1.0% 1.5% 2.0% 2.5% (millio

  29. Slide 29: ZECUITY Patent Protection

    29 ZECUITY Patent Protection •Issued patents provide protection into 2029 with pending applications into 2032 •Five issued US Patents (Orange Book listed) .Transdermal Methods and Systems for the Delivery of Anti-Migraine Compounds (April 2027) .U.S. 7,973,058 .U.S. 8,470,853 .Polyamine formulation

  30. Slide 30: ZECUITY - First and Only Approved Migraine Patch

    30 •Game-changing disruptive technology for migraine .Delivers sumatriptan, the #1 prescribed migraine medication .Five Orange-Book listed patents provide protection to April 2029 •Uniquely positioned to address migraine headache pain and MRN .Rapid relief of both headache pain and MRN with a low ra

  31. Slide 31: References

    31 References Slide 4 1.Lipton, R. Frequency and Burden of Headache-Related Nausea: Results from the American Migraine Prevalence and Prevention (AMPP) Study. Headache 2013; 53(1):93-103. 2.Lipton, R. Healthcare Resource Utilization and Direct Costs Associated with Frequent Nausea in Episodic Migrai

  32. Slide 32: References

    32 References Slide 9 1.National Headache Foundation Patient Survey (June 2008). 2.Silberstein, S. Migraine Symptoms: Results of a Survey of Self-reported Migraineurs. Headache 1995;35:387-396. 3.NuPathe market research (2008, 2011). 4.Dodick, D. Triptan Nonresponder Studies: Implications for Clinic

NuPathe — Investor Presentation (September 2013) on 6ix